Your browser doesn't support javascript.
loading
Clinical trial of gabexate in the prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis
Xiong, G. S; Wu, S. M; Zhang, X. W; Ge, Z. Z.
Afiliação
  • Xiong, G. S; Shanghai Second Medical University. Shanghai Institute of Digestive Disease. Renji Hospital.Department of Gastroenterology. Shanghai. CN
  • Wu, S. M; Shanghai Second Medical University. Shanghai Institute of Digestive Disease. Renji Hospital. Department of Gastroenterology. Shanghai. CN
  • Zhang, X. W; Shanghai Second Medical University. Renji Hospital. Department of Surgery. Shanghai. CN
  • Ge, Z. Z; Shanghai Second Medical University. Shanghai Institute of Digestive Disease. Renji Hospital. Department of Gastroenterology. Shanghai. CN
Rev. bras. pesqui. méd. biol ; Braz. j. med. biol. res;39(1): 85-90, Jan. 2006. tab
Article em En | LILACS | ID: lil-419156
Biblioteca responsável: BR1.1
ABSTRACT
The objective of the present study was to determine the efficacy of prophylactic administration of gabexate for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis, hyperamylasemia and pancreatic pain. Patients scheduled for ERCP were randomized into two groups in a double-blind manner the patients in the gabexate group were treated with continuous intravenous infusion of 300 mg gabexate dissolved in 500 mL Ringer's solution at 111 mL/h, starting 30 min before the endoscopic maneuvers and continuing up to 4 h after them; placebo group patients were treated only with Ringer's solution also starting 30 min before the endoscopic maneuvers and continuing up to 4 h. Data for 193 patients were analyzed. The incidence of post-ERCP pancreatitis was 3 patients (3.1 percent) in the gabexate group and 10 (10.5 percent) in the placebo group (P = 0.040). The incidence of hyperamylasemia was 33 patients (33.7 percent) in the gabexate group and 42 (43.7 percent) in the placebo group (P = 0.133). The incidence of pancreatic pain was 15 patients (15.3 percent) in the gabexate group and 28 (29.5 percent) in the placebo group (P = 0.018). The results suggest that a 4.5-h infusion of gabexate (for a total of 300 mg) could prevent post-ERCP pancreatitis and pancreatic pain.
Assuntos
Texto completo: 1 Coleções: 01-internacional Base de dados: LILACS Assunto principal: Pancreatite / Dor Abdominal / Inibidores de Serina Proteinase / Colangiopancreatografia Retrógrada Endoscópica / Gabexato / Hiperamilassemia Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: Braz. j. med. biol. res / Rev. bras. pesqui. méd. biol Assunto da revista: BIOLOGIA / MEDICINA Ano de publicação: 2006 Tipo de documento: Article País de afiliação: China País de publicação: Brasil
Texto completo: 1 Coleções: 01-internacional Base de dados: LILACS Assunto principal: Pancreatite / Dor Abdominal / Inibidores de Serina Proteinase / Colangiopancreatografia Retrógrada Endoscópica / Gabexato / Hiperamilassemia Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: Braz. j. med. biol. res / Rev. bras. pesqui. méd. biol Assunto da revista: BIOLOGIA / MEDICINA Ano de publicação: 2006 Tipo de documento: Article País de afiliação: China País de publicação: Brasil